Our Work
Latham & Watkins Advises EQT in Acquisition of TachoSil® Biosurgery Business from Corza Medical
July 7, 2026
Private Equity M&A team represents the global investment organization in the transaction.
EQT has announced that EQT X has agreed to acquire Corza Biosurgery from Corza Medical, comprising TachoSil®, a leading dual‑action active biologic patch that both controls bleeding and seals tissue during surgery. The transaction is subject to customary conditions and approvals. It is expected to close during Q4 2026.
Latham & Watkins LLP represents EQT in the transaction with a corporate deal team led by partners Alex Kelly, Eyal Orgad, and Paul Sheridan and counsel Richard Quay.